

---

SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934  
(Amendment No. 2)\*

**Larimar Therapeutics, Inc.**

---

(Name of Issuer)

**Common Stock, par value \$0.001 per share**

---

(Title of Class of Securities)

**517125100**

---

(CUSIP Number)

**12/31/2025**

---

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

- Rule 13d-1(b)  
 Rule 13d-1(c)  
 Rule 13d-1(d)
- 

SCHEDULE 13G

CUSIP No. 517125100

Names of Reporting Persons

1

Blue Owl Capital Holdings LP

Check the appropriate box if a member of a Group (see instructions)

2

(a)

(b)

3

Sec Use Only

Citizenship or Place of Organization

4

DELAWARE

	Sole Voting Power	
5		
	8,464,663.00	
Number of Shares Beneficially Owned by Each Reporting Person With:	Shared Voting Power	
6		
	0.00	
	Sole Dispositive Power	
7		
	8,464,663.00	
	Shared Dispositive Power	
8		
	0.00	
9	Aggregate Amount Beneficially Owned by Each Reporting Person	
	8,464,663.00	
10	Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)	
	<input type="checkbox"/>	
11	Percent of class represented by amount in row (9)	
	9.99 %	
12	Type of Reporting Person (See Instructions)	
	PN	

**Comment for Type of Reporting Person:** The reported securities represent (i) 6,823,690 shares of Common Stock and (ii) 1,640,973 shares of Common Stock issuable upon conversion of Series A Preferred Stock (as defined below). The percentage of class is calculated based upon 85,590,392 shares of Common Stock outstanding as of November 3, 2025, as reported on the Issuer's Form 10-Q filed with the Securities and Exchange Commission on November 5, 2025, as decreased by (i) 2,500,000 shares of the Issuer's Common Stock exchanged for Series A Convertible Preferred Stock, and increased by (ii) 1,640,973 shares of Common Stock issuable upon conversion of Series A Preferred Stock.

## SCHEDULE 13G

### Item 1.

Name of issuer:

- (a) Larimar Therapeutics, Inc.  
Address of issuer's principal executive offices:
- (b) Three Bala Plaza East, Suite 506, Bala Cynwyd, PA, 19004

### Item 2.

Name of person filing:

- (a) This statement is filed by the Blue Owl Capital Holdings LP, referred to herein as the "Reporting Person."  
Address or principal business office or, if none, residence:
- (b) 399 Park Avenue New York, New York 10022  
Citizenship:
- (c) See response to Item 4 on the cover page.  
Title of class of securities:
- (d) Common Stock, par value \$0.001 per share  
CUSIP No.:
- (e) 517125100

### Item 3. If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

- (a)  Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
- (b)  Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);

- (c)  Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
- (d)  Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
- (e)  An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
- (f)  An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
- (g)  A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
- (h)  A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
- (i)  A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
- (j)  A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
- (k)  Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).

Item 4. Ownership

Amount beneficially owned:

- (a) See response to Item 9 on the cover page. The reported securities include 6,823,690 shares of Common Stock and 1,640,973 shares of Common Stock issuable upon conversion of 250,000 shares of Series A convertible preferred stock (which would be convertible into 2,500,000 shares of Common Stock in the absence of a conversion blocker that limits the holder's beneficial ownership to 9.9%). The filing of this statement shall not be construed as an admission that the Reporting Person is, for the purpose of Section 13(d) or 13(g) of the Exchange Act, the beneficial owner of any securities covered by this statement.

Percent of class:

- (b) See response to Item 11 on the cover page. %

- (c) Number of shares as to which the person has:

(i) Sole power to vote or to direct the vote:

See response to Item 5 on the cover page.

(ii) Shared power to vote or to direct the vote:

See response to Item 6 on the cover page.

(iii) Sole power to dispose or to direct the disposition of:

See response to Item 7 on the cover page.

(iv) Shared power to dispose or to direct the disposition of:

See response to Item 8 on the cover page.

Item 5. Ownership of 5 Percent or Less of a Class.

Item 6. Ownership of more than 5 Percent on Behalf of Another Person.

Not Applicable

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

Not Applicable

Item 8. Identification and Classification of Members of the Group.

Not Applicable

Item 9. Notice of Dissolution of Group.

Not Applicable

Item 10. Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Blue Owl Capital Holdings LP

Signature: /s/ Karen Hager

Name/Title: Karen Hager / Chief Compliance Officer

Date: 02/12/2026